Trioxsalen
Trioxsalen is a psoralen compound (furocoumarin) that intercalates into DNA and, upon activation by ultraviolet A (UVA) light, forms covalent crosslinks between DNA strands, inhibiting cellular proliferation. It is used in photochemotherapy (PUVA) for skin conditions such as vitiligo and mycosis fungoides, and has been investigated as a photosensitizing agent in certain cancers including bladder and breast cancer. Its photodynamic mechanism requires careful UV exposure control to minimize side effects.
Masse moléculaire
228,2400 g/mol
LogP
3,00
TPSA
39,40 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Structure 2D
Cite this structure
Embed this structure
SMILES
Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
InChI
InChI=1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3
Molecular Formula
C14H12O3
HBD / HBA
- / 3
Liaisons Rotatives
0
Atomes Lourds
17
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Trioxsalen is a psoralen compound (furocoumarin) that intercalates into DNA and, upon activation by ultraviolet A (UVA) light, forms covalent crosslinks between DNA strands, inhibiting cellular proliferation. It is used in photochemotherapy (PUVA) for skin conditions such as vitiligo and mycosis fungoides, and has been investigated as a photosensitizing agent in certain cancers including bladder and breast cancer. Its photodynamic mechanism requires careful UV exposure control to minimize side effects.
Accumulates in target tissues and generates reactive oxygen species upon activation by specific wavelengths of light, causing localized cellular damage and destruction of pathological tissue.
Yes, Trioxsalen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1475. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5585. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trioxsalen"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trioxsalen/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trioxsalen/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trioxsalen/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trioxsalen"></drugfyi-drug>